- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05698329
Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME
A Phase 1 Study of the Safety, Pharmacokinetics, and Exploratory Efficacy of Periocular Administration of AIV007 in Subjects With Macular Edema Secondary to Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
AIV007 is a multiple kinase inhibitor of vascular endothelial growth factor receptors (VEGFR 1, -2 & -3); fibroblast growth factor receptors (FGFR-1, -2, -3 & -4); and platelet-derived growth factor receptors (PDGFR-α & β)1. Lenvatinib is the active pharmaceutical ingredient in AIV007 formulation that is FDA-approved for oral administration for patients with advanced renal cell carcinoma (RCC), differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), and advanced endometrial carcinoma.
. AiViva BioPharma, Inc. (AiViva) has developed a novel, thermoresponsive gel suspension of AIV007 for periocular administration to form a durable depot. This monotherapy is in development for the treatment of retinal and choroidal vascular disease (i.e., neovascular age-related macular degeneration (nAMD) & diabetic macular edema (DME)). For preclinical and clinical (AIV007-E02) studies using periocular administration, AIV007 is injected outside the eyeball and the depot forms a soft mass, referred to as posterior juxtascleral depot (PJD) placement.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
California
-
Beverly Hills, California, Verenigde Staten, 90211
- Retina-Vitreous Associates
-
Santa Ana, California, Verenigde Staten, 92705
- Orange County Retina
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Verum Research
-
-
Texas
-
McAllen, Texas, Verenigde Staten, 78503
- Valley Retina Institute
-
Plano, Texas, Verenigde Staten, 75075
- Texas Retina Associates
-
San Antonio, Texas, Verenigde Staten, 78240
- Medical Center Ophthalmology
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
General inclusion Criteria:
- Male or female subjects aged 21-90 years (inclusive) at screening
- BCVA in the study eye at screening and baseline/Day 1: ETDRS letter score ≤ 75 and ≥ 24 (20/32 to 20/330 Snellen equivalent)
- Subject must have received treatment within the 24 months before screening with intravitreal (IVT) injections of an anti-VEGF agent with the last anti-VEGF injection in the study eye being at least 6 weeks (42 days) before baseline/Day 1.
- Subject has documentation of anti-VEGF responsiveness
- Subject must provide written informed consent before any study-related procedures are performed
- Clear ocular media and adequate pupil dilation in both eyes to permit good-quality photographic imaging
nAMD subject
- The active choroidal neovascularization (CNV) is confirmed by fluorescein angiography (FA; evidence of leakage)
- Residual intraretinal or subretinal fluid based on SD-OCT
- CST ≥ 300 µm as assessed by SD-OCT
- Total lesion size < 10 disc areas (25.4 mm2)
- Absence of geographic atrophy within 200 µm of the fovea
- If subretinal hemorrhage is present, it must be < 50% of the total CNV lesion and/or not involve the fovea
- If fibrosis is present, it must be <50% of the total lesion area
DME subject
- Diagnosis of diabetes mellitus (Type 1 or Type 2)
- Subject has clinically significant DME with central involvement (CST≥300 μm by OCT)
- The decrease in vision in the study eye was determined by the investigator to be primarily the result of DME
Exclusion Criteria:
- Previous treatment for nAMD or DME in the study eye other than standard-of-care anti-VEGF IVT injection, e.g., cell therapy, brachytherapy, gene therapy
- Uncontrolled intraocular pressure (IOP), defined as an IOP > 25 mmHg
- Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) >10% at screening visit
- The spherical equivalent for refractive error in the study eye of worse than 8.0 diopters of myopia (before cataract or refractive surgery) per the current prescription
- Any history of active bacterial, viral, fungal, or parasitic ocular or periocular infection, or intraocular inflammation in either eye within the 30 days before the screening Visit
- History of vitreous hemorrhage within 3 months before screening in the study eye
- Uncontrolled systemic disease or any other condition or therapy that would make the participant unsuitable for the study
- Participation in any investigational study within 60 days before the screening visit, or planned use of an investigational product or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives)
- History of allergy or hypersensitivity to constituents of the study treatment formulation, topical iodine, ocular antimicrobial solutions, or clinically relevant hypersensitivity to fluorescein
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: AIV007 low dose
Periocular injection, low dose |
Periocular injection |
|
Experimenteel: AIV007 intermediate dose 1
Periocular injection, intermediate dose 1 |
Periocular injection |
|
Experimenteel: AIV007 intermediate dose 2
Periocular injection, intermediate dose 2 |
Periocular injection |
|
Experimenteel: AIV007 intermediate dose 3
Periocular injection, intermediate dose 3 |
Periocular injection |
|
Experimenteel: AIV007 intermediate dose 4
Periocular injection, intermediate dose 4 |
Periocular injection |
|
Experimenteel: AIV007 High dose
Periocular injection, high dose |
Periocular injection |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse Events
Tijdsspanne: Approximately 168 days
|
Incidence of adverse events and serious adverse events |
Approximately 168 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean change from baseline in best-corrected visual acuity (BCVA)
Tijdsspanne: Approximately 168 days
|
Number of Early Treatment Diabetic Retinopathy Study (ETDRS) letters |
Approximately 168 days
|
|
Mean change from baseline in central subfield thickness as measured by spectral domain optical coherence tomography (SD-OCT)
Tijdsspanne: Approximately 168 days
|
SD-OCT read by a central reading center |
Approximately 168 days
|
|
Mean time to rescue medication
Tijdsspanne: Approximately 168 days
|
number of days to receive rescue medication |
Approximately 168 days
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AIV007-E02
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .